Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily S&P Biotech Bull 3X ETF (LABU)

Ticker LABU · Index fund · · Holdings as of Jul 31, 2026

Expense ratio
0.96%$96/yr per $10k
5-yr return
−39.6%annualized
1-yr return
+78.7%as of Dec 2025
Net assets
$494.4Mall share classes
Holdings
163

Bottom line

Is LABU a good fund? The bottom line

LABU is an index leveraged & inverse ETF from Direxion.

It charges 0.96% — about $96 a year on every $10,000 invested, cheaper than 80% of leveraged & inverse funds we track.

It returned +78.7% over one year, −39.6% a year over five years, −20.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $494 million in net assets and 163 holdings, its largest position is Dreyfus (15.9%) and the top 10 make up 64.8% of the portfolio.

What stands out

  • Low cost: cheaper than 80% of leveraged & inverse peers

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 64.8% of assets
  • High turnover (107% a year) can mean more taxable distributions

Updated Nov 19, 2026

What LABU invests in

The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). GICS classifications are determined primarily based on a companys revenues, however, earnings and market perception are also considered by GICS. The Index consists of constituents of the S&P Total Market Index (S&P TMI) that belong to the GICS biotechnology sub-industry that satisfy the following criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%…

From the fund's prospectus (filed Mar 3, 2026).

LABU performance

Fund calendar-year total returns, 2016–2025 2016: −63.0%; 2017: +148.7%; 2018: −57.3%; 2019: +74.6%; 2020: +74.7%; 2021: −64.3%; 2022: −80.3%; 2023: −13.4%; 2024: −25.9%; 2025: +78.7% −63% 2016 +149% 2017 −57% 2018 +75% 2019 +75% 2020 −64% 2021 −80% 2022 −13% 2023 −26% 2024 +79% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
LABU+78.7%−39.6%−20.8%
Leveraged & Inverse median−7.7%−11.8%−13.5%

Source: Fund prospectus, as of Dec 31, 2025

Full LABU performance history →

What LABU costs

On a $10,000 investment, LABU's 0.96% expense ratio costs about $96 a year. The prospectus estimates $1,178 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full LABU fee table →

LABU top 10 holdings

#Holding% of fund
1Dreyfus15.86%
2Goldman Financial14.83%
3N/a9.63%
4N/a7.30%
5Goldman Sachs Liq Es Fd A5.35%
6N/a4.85%
7N/a3.87%
8Apogee Therapeutics Inc APGE1.11%
9Oruka Therapeutics Inc ORKA1.03%
10Dianthus Therapeutics Inc DNTH0.96%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 64.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to LABU

More funds like LABU →

LABU FAQ

What is the expense ratio of LABU?
LABU's expense ratio is 0.96%, which works out to about $96 a year for every $10,000 invested. The prospectus estimates total costs of $1,178 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LABU a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 80% of leveraged & inverse peers; 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 64.8% of assets; high turnover (107% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does LABU hold?
LABU's largest holdings are Dreyfus (15.9%), Goldman Financial (14.8%), N/a (9.6%), N/a (7.3%), Goldman Sachs Liq Es Fd A (5.4%). It holds 163 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is LABU's 5-year return?
LABU returned −39.6% a year over the five years ending Dec 31, 2025, and −20.8% a year over ten years. Past performance does not guarantee future results.
Who manages LABU?
LABU is offered by Direxion through Direxion Shares ETF Trust.